Sydney, Dec 22, 2014 (ABN Newswire) - Melbourne technology firm, Rhinomed (ASX:RNO) is pleased to announce that it has received a Research and Development tax refund of $570,337.
Rhinomed Limited intends to apply these funds to continue the development and commercialization of its BreatheAssist platform technology and for working capital purposes.
About Rhinomed Ltd
Rhinomed Limited ASX:RNO
Rhinomed Limited is a medical technology firm that focuses on nasal, respiratory and breathing management technologies. The company is monetising its technology portfolio in the Sport and recreation market, Sleep, Wellbeing and Drug delivery markets.
Rhinomed’s technology is designed to radically improve the way you breathe sleep, maintain your health and take medication.
The first product brought to market is the Turbine(TM). A radical nasal technology that improves airflow by an average of 38%, the Turbine(TM) is an internal nasal dilator that has since it’s launch in January 2014 in Australia, grown to be widely adopted by leading cyclists and triathletes globally.
Now shipped to over 36 countries and with a growing global distribution base, the Turbine(TM) is providing all those undertaking aerobic activities with an opportunity to breathe better, perform better and get more enjoyment from their sport and exercise.
TwitterFollow the Turbine on Twitter at @theturbinecom
Follow Mute Snoring on Twitter at @mutesnoring
Contact
Michael Johnson
CEO & Managing Director
T: +61-3-8416-0900
mjohnson@rhinomed.com.au
Help employers find you! Check out all the jobs and post your resume.
